{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000063","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-08-06T11:12:47+00:00","discovered_at":"2026-08-06T11:15:03.438163+00:00","generated_at":"2026-08-06T11:15:06.486182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Q2 revenue $92.1M (+29% YoY); Recorlev up 81%; tightens FY guidance to $385-390M","bullets":["Net product revenue $91.0M (+34% YoY); Recorlev $56.8M (+81%), Gvoke $22.5M (-4%), Keveyis $11.7M (+2%).","Net loss $31.1M includes ~$31M non-cash charge from 2028 Convertible Notes exchange; adjusted EBITDA $19.3M (+$6.7M YoY).","Gross margin improved to 86% (Q2 2025: 82%) on favorable product mix.","Full-year 2026 total revenue guidance tightened to $385-390M from prior range.","USPTO Notice of Allowance for new Keveyis patent expected to extend IP protection through at least 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000063","json":"https://secwatch.observer/filing/0001867096-26-000063.json","markdown":"https://secwatch.observer/filing/0001867096-26-000063.md","text":"https://secwatch.observer/filing/0001867096-26-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/0001867096-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/xers-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:15:06.486182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}